Hinge Health, Inc.
No SEC Form 4 filings for $HNGE in the last 30 days.
See all $HNGE insider activity →Hinge Health (HNGE) reported Q2 earnings on 4 Aug 2026, raised full-year guidance, updated its share buyback activity, and outlined expansion in digital gastrointestinal care. The stock closed at $89.33, with recent returns of 11.55% (1 day), 19.57% (7 days), and 59.46% (90 days). A valuation narrative cites fair value $90.87 and a P/E of 64.4x.
Simply Wall St reports Hinge Health (HNGE) shares rose about 47% over three months and fell about 9% over one month, then gained 1.7% after Q2. The article cites Q2 revenue of about $213m, operating income $62m, operating margin near 29%, and free cash flow $100m, plus revenue up to $212.8m from $139.1m YoY.
Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.
Over the past 7 days, alphai's AI scored 4 news stories mentioning HNGE (Hinge Health, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent HNGE coverage spans financial news, earnings and insider activity.
The article frames a valuation re-rate risk around raised guidance and buyback updates, but also flags adoption and AI-regulatory margin swing factors.
Margin and cash-flow strength support a bullish re-rating narrative, but the article flags ongoing investment and timing risks (HingeSelect and Cylinder).
The stock move is driven by a large earnings surprise plus above-consensus forward guidance and an adjacent-market acquisition, likely sustaining momentum near-term.
The PT raise is tied to a new GI expansion deal plus upside operating leverage from the quarter, supporting a near-term positive re-rating thesis.
The article frames a positive fundamental reset for Hinge Health via beat plus higher full-year guidance, with momentum reinforced at an investor day and early migraine-product reception.
alphai scores every news story that mentions HNGE with an AI model for sentiment and relevance, and aggregates insider trades from Hinge Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Hinge Health (HNGE) reported Q2 earnings on 4 Aug 2026, raised full-year guidance, updated its share buyback activity, and outlined expansion in digital gastrointestinal care. The stock closed at $89.33, with recent returns of 11.55% (1 day), 19.57% (7 days), and 59.46% (90 days). A valuation narrative cites fair value $90.87 and a P/E of 64.4x.
7 min readSimply Wall St reports Hinge Health (HNGE) shares rose about 47% over three months and fell about 9% over one month, then gained 1.7% after Q2. The article cites Q2 revenue of about $213m, operating income $62m, operating margin near 29%, and free cash flow $100m, plus revenue up to $212.8m from $139.1m YoY.
6 min readHinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.
4 min readInvesting.com reports Citizens raised its price target for Hinge Health Inc (HNGE) to $107 from $96 and kept a Market Outperform rating. The firm cited Hinge’s plan to expand into gastrointestinal care via a $105 million acquisition of Cylinder Health. Hinge reported Q2 2026 revenue of $212.8M, up 53% YoY, and billings of $288.5M.
4 min readMeridian Small Cap Growth Fund’s Q2 2026 investor letter, managed by ArrowMark Partners, reported a 21.54% return for the quarter ended June 30, 2026, versus the Russell 2000 Growth Index’s 25.71%. The letter highlighted Hinge Health (NYSE:HNGE), citing a sharp share rise after an earnings beat and full-year guidance increase, plus new long-term targets and a migraine product update.
4 min readFifth Third Bancorp disclosed a new first-quarter position in Hinge Health Inc. (NYSE:HNGE), buying 35,209 shares worth about $1.36M, per its SEC filing. Other funds also adjusted HNGE stakes. Analysts cited price targets ranging from $45 to $97. Hinge Health reported $0.45 EPS and $182.31M revenue for the quarter.
5 min readInsight Holdings Group sold 426,000 shares of Hinge Health, Inc. (HNGE) on July 7 and July 9, 2026 for about $38.4 million, per an SEC Form 4. The sales followed conversion of 426,171 options liquidated at a weighted average $90.21. Hinge Health had TTM revenue of $646.3 million and a net loss of $510.3 million.
3 min readInsight Holdings Group, LLC sold 426,171 indirectly-held shares of Hinge Health, Inc. (HNGE) at an average of $90.21 ($90.17–$91.00, $38.45M total) across 12 trades over 2026-07-07 to 2026-07-09 under a Rule 10b5-1 trading plan.
2 min readMecklenburg Gabriel M.I. sold 83,334 shares of Hinge Health, Inc. (HNGE) at an average of $85.05 ($82.97–$86.51, $7.09M total) across 5 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readInsight Holdings Group, LLC sold 1,466,667 indirectly-held shares of Hinge Health, Inc. (HNGE) at an average of $82.83 ($81.30–$84.59, $121.49M total) across 20 trades on 2026-06-29 under a Rule 10b5-1 trading plan.
2 min read
